PREVIN combines a novel drug delivery method to treat patients with Diabetic Retinopathy (DR) (i.e. blindness in Diabetes patients) with established drugs.
This method will improve localized drug delivery with cyclodextrin nanoparticles to the back of the eye for effective, safe, low-cost, preventive and non-invasive treatment of Diabetic Retinopathy. PREVIN, supported by extensive safety and efficacy studies, will be ready for licensing within one year after the end of the project.Participants in the project are the Medical University Of Vienna, Oculis Pharma, Experimentica Ltd, University Of Copenhagen, Zealand University Hospital and Nucro-technics, A Division Of The Vimy Ridge Group Ltd.
The project was awarded a Eurostars grant.